Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $15.0 million.

  • Precision Biosciences' Total Current Liabilities rose 2515.44% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 2515.44%. This contributed to the annual value of $15.0 million for FY2024, which is 7003.22% down from last year.
  • Per Precision Biosciences' latest filing, its Total Current Liabilities stood at $15.0 million for Q3 2025, which was up 2515.44% from $13.6 million recorded in Q2 2025.
  • In the past 5 years, Precision Biosciences' Total Current Liabilities registered a high of $63.8 million during Q1 2021, and its lowest value of $12.0 million during Q3 2024.
  • In the last 5 years, Precision Biosciences' Total Current Liabilities had a median value of $36.3 million in 2021 and averaged $37.6 million.
  • As far as peak fluctuations go, Precision Biosciences' Total Current Liabilities surged by 16853.98% in 2021, and later crashed by 7632.81% in 2024.
  • Over the past 5 years, Precision Biosciences' Total Current Liabilities (Quarter) stood at $36.0 million in 2021, then skyrocketed by 65.83% to $59.7 million in 2022, then fell by 16.22% to $50.0 million in 2023, then tumbled by 70.03% to $15.0 million in 2024, then rose by 0.11% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q3 2025, $13.6 million for Q2 2025, and $12.4 million during Q1 2025.